Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(4-chlorophenyl)-1-(4-(7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
2. Gdc-0068
3. Gdc0068
1. Gdc-0068
2. 1001264-89-6
3. Ipatasertib (gdc-0068)
4. Rg7440
5. Rg-7440
6. Gdc0068
7. Gdc 0068
8. Gdc-0068 (rg7440)
9. 524y3ib4hq
10. (s)-2-(4-chlorophenyl)-1-(4-((5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
11. Chembl2177390
12. Rg 7440
13. (2s)-2-(4-chlorophenyl)-1-(4-((5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl(-3-((propan-2-yl)amino)propan-1-one
14. (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-6,7-dihydro-7-hydroxy-5-methyl-5h-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-1-propanone
15. (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one
16. 1-propanone, 2-(4-chlorophenyl)-1-(4-((5r,7r)-6,7-dihydro-7-hydroxy-5-methyl-5h-cyclopentapyrimidin-4-yl)-1-piperazinyl)-3-((1-methylethyl)amino)-, (2s)-
17. (2s)-2-(4-chlorophenyl)-1-{4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl}-3-(propan-2-ylamino)propan-1-one
18. Ipatasertib [inn]
19. Ipatasertib [usan:inn]
20. Unii-524y3ib4hq
21. Mfcd22124514
22. 1-propanone, 2-(4-chlorophenyl)-1-[4-[(5r,7r)-6,7-dihydro-7-hydroxy-5-methyl-5h-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-, (2s)-
23. Gdc0068 Di-hcl
24. Ipatasertib (usan/inn)
25. Ipatasertib [usan]
26. Gdc-0068 Di-hcl
27. Ipatasertib; Gdc-0068
28. Rg-7440 Di-hcl
29. Ipatasertib [who-dd]
30. Schembl191659
31. Gtpl7887
32. Chebi:95089
33. Dtxsid101025595
34. Ex-a2077
35. Bdbm50398379
36. Nsc767898
37. Nsc781451
38. Nsc800986
39. Nsc832484
40. S2808
41. Zinc68250459
42. Akos025396463
43. Bcp9000712
44. Ccg-269312
45. Cs-0975
46. Db11743
47. Nsc-767898
48. Nsc-781451
49. Nsc-800986
50. Nsc-832484
51. Ncgc00346714-01
52. 2-(4-chlorophenyl)-1-(4-(7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
53. Ac-28420
54. As-17027
55. Hy-15186
56. Bcp0726000195
57. J3.478.537f
58. D10641
59. Q27078088
60. (2s)-2-(4-chlorophenyl)-1-[4-[(5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[e]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one
61. 0rf
| Molecular Weight | 458.0 g/mol |
|---|---|
| Molecular Formula | C24H32ClN5O2 |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 457.2244530 g/mol |
| Monoisotopic Mass | 457.2244530 g/mol |
| Topological Polar Surface Area | 81.6 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 622 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of breast cancer , Treatment of prostate cancer
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
68
PharmaCompass offers a list of Ipatasertib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ipatasertib manufacturer or Ipatasertib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ipatasertib manufacturer or Ipatasertib supplier.
PharmaCompass also assists you with knowing the Ipatasertib API Price utilized in the formulation of products. Ipatasertib API Price is not always fixed or binding as the Ipatasertib Price is obtained through a variety of data sources. The Ipatasertib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ipatasertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ipatasertib, including repackagers and relabelers. The FDA regulates Ipatasertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ipatasertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ipatasertib supplier is an individual or a company that provides Ipatasertib active pharmaceutical ingredient (API) or Ipatasertib finished formulations upon request. The Ipatasertib suppliers may include Ipatasertib API manufacturers, exporters, distributors and traders.
Ipatasertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ipatasertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ipatasertib GMP manufacturer or Ipatasertib GMP API supplier for your needs.
A Ipatasertib CoA (Certificate of Analysis) is a formal document that attests to Ipatasertib's compliance with Ipatasertib specifications and serves as a tool for batch-level quality control.
Ipatasertib CoA mostly includes findings from lab analyses of a specific batch. For each Ipatasertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ipatasertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Ipatasertib EP), Ipatasertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ipatasertib USP).
